MODULATION OF INVARIANT NATURAL KILLER T CELLS IN THE TREATMENT OF SEPSIS

摘要

The present disclosure is directed to the modulation of in variant Natural Killer T Cells (iNKT Cells) using a Th2 -polarizing iNKT Cell agonist, such as an α-galactosylceramide, synthetic glycolipid OCH, or C20:2 α-galactosylceramide analog. Said Th2 -polarizing iNKT Cell agonists are used the treatment of sepsis and/or apoptosis in a subject. A method of diagnosing early stage sepsis in a subject by measuring a ratio of circulating iNKT cells relative to total circulating T cells in a subject is also disclosed.